Figure legends
Figure 1. SHR2554 drug–drug interaction study design: effect of
coadministration of SHR2554 with rifampicin, compared with SHR2554
alone, on the pharmacokinetic profile of SHR2554 in Chinese healthy male
volunteers.
Figure 2. Linear (A) and semilog (B) plasma concentration–time curves
for SHR2554 after administration
alone (300 mg) and coadministered with rifampicin (600 mg) in Chinese
healthy volunteers. When ≥50% of the concentration data at a single
time point were defined as BLQ, the mean concentration at that time
point was set to BLQ. BLQ data were set to 0 on the linear scale and are
not presented on the semilog scale. Error bars represent standard
deviation. A Nominal time after dose: planned sampling time postdose.
BLQ, below the limit of quantification.
Figure 3. Forest plot of the effect of coadministration of SHR2554 with
rifampicin compared with SHR2554 alone on the exposure parameters of
SHR2554 in Chinese healthy volunteers. AUC0–last, area
under the concentration–time curve from time 0 to the last quantifiable
concentration; AUC0–inf, area under the
concentration–time curve from time 0 to infinity; CI, confidence
interval; Cmax, maximum plasma concentration; GM,
geometric mean.
Table1 Summary of subject baseline and demographic characteristics (full
analysis set).